Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.590

+3.6%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cautious_Optimist who wrote (343)	2/21/2012 3:34:44 AM
From: PLegee	2 Recommendations of 368

The Shire deal changes everything in my opinion, plus gives me a much needed boost regarding managerial competence. I think the recent inclusion of Ringo on the Board has already started paying big dividends and his influence had a lot to do with this deal reaching a successful conclusion. This is finally a validation of the company's clinical platform based upon the accolades of Wall St and pharma alike. The partnership is better and more significant than I was previously giving the company's management the credit to achieve. Congrats to Sangamo on this huge step forward, it was long, long overdue. Looking at the stock going forward, it will be up from here. The upcoming CROI will also unveil some additional HIV updates which the company has strategically maintained complete control over; it is not part of the Shire hemo related deal. Ed has already implied that the HIV trials have been designed to produce maximum effect, I think Phase II updates will be very encouraging (as do most investors). Looks like the newfound momentum continues near term. Now that the "ice has been cracked", SGMOs potential on hundreds of further mono genetic target opportunities can at least be put into play for other partnership discussions/deals. The significance of the Shire deal cannot be understated; it is a huge step forward for the company. Though Ed will maintain this has been his corp strategy all along, it was the new blood on the B of D that actually influenced the successful outcome of the partnership. This truly is a major milestone for the company and ultimately for patient access to game changing science.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next